You have access
18-OR: Efficacy and Safety of Chiglitazar vs. Sitagliptin in Patients with Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Noninferiority Phase 3 Trial (CMAS)
WEIPING JIA, JIANHUA MA, HENG MIAO, CHANGJIANG WANG, XIAOYUE WANG, QUANMIN LI, WEIPING LU, JIALIN YANG, LIHUI ZHANG, JINKUI YANG, GUIXIA WANG, XIUZHENG ZHANG, MIN ZHANG, LI SUN, XUEFENG YU, JIANLING DU, BINGYIN SHI, CHANGQING XIAO, DALONG ZHU, HONG LIU, LIYONG ZHONG, CHUN XU, QI XU, GANXIONG LIANG, YING ZHANG, GUANGWEI LI, MINGYU GU, JUN LIU, ZHIQIANG NING, LINONG JI
Diabetes Jun 2019, 68 (Supplement 1) 18-OR; DOI: 10.2337/db19-18-OR